LynnMarieMalecMD

Oncology • Milwaukee, WI

Hematologic Oncology

Physician

Join to view full profile

Dr. Malec is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Malec's full profile

Already have an account?

Office
9200 W Wisconsin Ave
Milwaukee, WI 53226
Phone(414) 805-4600
Fax(414) 805-4606
Is this information wrong?

Education & Training

University of Pittsburgh Medical CenterFellowship, Pediatric Hematology/Oncology, 2011 - 2014
University of Pittsburgh Medical CenterResidency, Internal Medicine/Pediatrics, 2006 - 2010
University of Wisconsin School of Medicine and Public HealthClass of 2006

Certifications & Licensure

WI State Medical License 2016 - 2021
PA State Medical License 2006 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Phase II Single-Arm Trial of Preemptive Prophylaxis With Long-Acting Recombinant Factor VIII Fc Fusion Protein, Eloctate, to Prevent Inhibitor Formation in Children With Severe Hemophilia A Start of enrollment: 2015 Jul 01Ragni, M.V.

Publications & Presentations

PubMed

Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A.
Ebbert, P. T., Xavier, F., Malec, L. M., Seaman, C. D., Ragni, M. V.> ;Thrombosis research. 2020 Jul 13
The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States.
Malec, L. M., Cheng, D., Witmer, C. M., Jaffray, J., Kouides, P. A., Haley, K. M., Sidonio, R. F., Johnson, K., Recht, M., White, G., Croteau, S. E., Ragni, M. V.> ;American journal of hematology. 2020 May 2
Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres.
Malec, L. M., Croteau, S. E., Callaghan, M. U., Sidonio, R. F.> ;Haemophilia : the official journal of the World Federation of Hemophilia. 2020 Mar 7
Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and s...
Stacy E. Croteau, Dunlei Cheng, Alice J. Cohen, Chris E. Holmes, Lynn M. Malec, Michael Silvey, Courtney D. Thornburg, Allison P. Wheeler, Peter A. Kouides, Leslie Raf...> ;Haemophilia. 2019 Jul 1
rFIXFc for Immune Tolerance Induction in a Severe Hemophilia B Patient with an Inhibitor and Prior History of ITI Related Nephrotic Syndrome.
Lynn Malec, Thomas C. Abshire, Shawn M. Jobe, Gilbert C. White> ;Haemophilia. 2018 Jul 1
Prophylactic rtPA in the Prevention of Line-associated Thrombosis and Infection in Short Bowel Syndrome.
Lynn M. Malec, James D. Cooper, Jeffrey A. Rudolph, Marian G. Michaels, Margaret V. Ragni> ;Journal of Pediatric Gastroenterology and Nutrition. 2017 Nov 1
Feasibility of the Von Willebrand disease PREVENT trial.
Ragni, M. V., Machin, N., James, A. H., Seaman, C. D., Malec, L. M., Kessler, C. M., Konkle, B. A., Kouides, P. A., Neff, A. T., Philipp, C. S., Brooks, M. M.> ;Thrombosis research. 2017 Jun 4
Extended half-life factor VIII for immune tolerance induction in haemophilia.
Malec, L. M., Journeycake, J., Ragni, M. V.> ;Haemophilia : the official journal of the World Federation of Hemophilia. 2016 Sep 20
Von Willebrand factor for menorrhagia: a survey and literature review.
Margaret V. Ragni, Nicoletta Machin, Lynn M. Malec, Andra H. James, Craig M. Kessler, B. A. Konkle, Peter A. Kouides, Anne T. Neff, Claire S. Philipp, Donald Brambilla> ;Haemophilia. 2016 May 1
Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction.
Margaret V. Ragni, Donna DiMichele, C. M. Hay, Lynn M. Malec, Craig D. Seaman, Jie Li, Jonathan G. Yabes, Saulius Butenas, Kathleen E. Brummel-Ziedins> ;Haemophilia. 2016 Mar 1
Validation Study of the Composite Score to Identify Von Willebrand Disease in Children.
Lynn M. Malec, Charity G. Moore, Carolyn M. Bennett, Donald L. Yee, Bryce A. Kerlin, Char Witmer, Roshni Kulkarni, Sweta Gupta, Sriya Gunawardena, Peter A. Kouides, De...> ;Journal of Pediatric Hematology Oncology. 2016 Mar 1
Postpartum haemorrhage in women with von Willebrand disease: an observational study of the Pennsylvania Health Care Cost Containment Council (PHC4) database
Lynn M. Malec, Charity G. Moore, Jonathan G. Yabes, Jie Li, Margaret V. Ragni> ;Haemophilia. 2015 Sep 1
2 citations
Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.
Ragni, M. V., Malec, L. M.> ;Expert review of hematology. 2014 Nov 7
Join now to see all

Abstracts/Posters

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial
Lynn M. Malec, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after Von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database
Lynn M Malec, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019